Prostate cancer screening with Prostate-Specific Antigen (PSA) testing: A retrospective study
Author:
Open Access
- 16 October 2024
- journal article
- research article
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 40 (10) , 2324-2330
Abstract
Objective: To evaluate the results of the prostate-specific antigen (PSA) test used in prostate cancer screening. Methods: This retrospective study was conducted on a total of 1106 male individuals, including 615 people (55.6%) aged 40-54, 379 people (34.3%) aged 55-69, and 112 individuals (10.1%) aged 70 and over. In the study, prostate-specific antigen (PSA) blood test results were performed on a total of 1106 male individuals aged 40 and over registered in the Uludag University Family Health Center, Bursa, Turkey during the 5-years between June 1, 2018, and May 31, 2023, were taken from the database and analyzed. Relationships with sociodemographic characteristics, comorbidities, and risk factors were examined. Data was analyzed using SPSS 25. Results: About 15.5% of the participants were married, 78.4% were single, and 6% were separated from their spouses or widows. The PSA values of the patients referred to the urologist were found to be significantly different between the ages of 55 and 69. It was determined that the PSA levels of the patients with benign prostatic hypertrophy and prostate cancer were higher than the patients without any finding, and the mean was 6.81±4.39 (p=0.01). Conclusion: In our study, it is important to diagnose benign prostatic hypertrophy or prostate cancer in patients aged 55-69 years, whose mean PSA levels were 6.81±4.39, and referred to a urologist. As a contribution to the discussions in the literature, we recommend that the patient with symptoms be referred to the urologist after the test request and the joint decision with the family physician. doi: https://doi.org/10.12669/pjms.40.10.8558 How to cite this: Goktas O. Prostate cancer screening with prostate-specific antigen (PSA) testing: A retrospective study. Pak J Med Sci. 2024;40(10):2324-2330. doi: https://doi.org/10.12669/pjms.40.10.8558 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Keywords
This publication has 20 references indexed in Scilit:
- Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998–2017British Journal of General Practice, 2020
- Reliability and validity test of VES-13 and analysis of influencing factors for the vulnerable condition of patients with advanced castration-resistant prostate cancerPakistan Journal of Medical Sciences, 2020
- Intensity modulated radiotherapy in combination with endocrinotherapy in the treatment of middle and advanced Prostatic CancerPakistan Journal of Medical Sciences, 2019
- PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline ChangesJournal of the National Comprehensive Cancer Network, 2019
- PSA-Screening und molekulare MarkerDer Urologe, 2019
- Transurethral balloon dilatation of the Prostate and Transurethral Plasmakinetic resection of the Prostate in the treatment of Prostatic HyperplasiaPakistan Journal of Medical Sciences, 2018
- Screening for Prostate CancerJAMA, 2018
- Prostate-Specific Antigen–Based Screening for Prostate CancerJAMA, 2018
- Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer MortalityJAMA, 2018
- Impact of polymorphisms of the DNA repair gene XRCC1 and their role in the risk of prostate cancerPakistan Journal of Medical Sciences, 2015